Department of Gastrointestinal Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.
Institute of Immunology and Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
J Zhejiang Univ Sci B. 2022 Oct 15;23(10):812-822. doi: 10.1631/jzus.B2200174.
Tertiary lymphoid structures (TLSs) are formations at sites with persistent inflammatory stimulation, including tumors. These ectopic lymphoid organs mainly consist of chemo-attracting B cells, T cells, and supporting dendritic cells (DCs). Mature TLSs exhibit functional organization for the optimal development and collaboration of adaptive immune response, delivering an augmented effect on the tumor microenvironment (TME). The description of the positive correlation between TLSs and tumor prognosis is reliable only under a certain condition involving the localization and maturation of TLSs. Emerging evidence suggests that underlying mechanisms of the anti-tumor effect of TLSs pave the way for novel immunotherapies. Several approaches have been developed to take advantage of intratumoral TLSs, either by combining it with therapeutic agents or by inducing the neogenesis of TLSs.
三级淋巴结构 (TLSs) 是在持续性炎症刺激部位形成的结构，包括肿瘤。这些异位淋巴器官主要由趋化性 B 细胞、T 细胞和支持性树突状细胞 (DCs) 组成。成熟的 TLSs 表现出适应性免疫反应的最佳发育和协作的功能组织，对肿瘤微环境 (TME) 产生增强效应。只有在 TLSs 的定位和成熟涉及一定条件下，TLSs 与肿瘤预后之间的正相关描述才是可靠的。新出现的证据表明，TLSs 的抗肿瘤作用的潜在机制为新型免疫疗法铺平了道路。已经开发了几种方法来利用肿瘤内 TLSs，方法是将其与治疗剂结合或诱导 TLSs 的新生。
